Salian Sujith Raj, Daddangadi Akshatha, Predheepan Dhakshanya, Bhagat Amonkar Divya Deeleep, Pandya Riddhi Kirit, Laxminarayana Sindhura Lakshmi Koulmane, Uppangala Shubhashree, Kalthur Guruprasad, Anderson Richard A, Adiga Satish Kumar
Centre of Excellence in Clinical Embryology, Department of Reproductive Science, Kasturba Medical College, Manipal. Manipal Academy of Higher Education, Manipal, 576 104, India.
Department of Pathology, Kasturba Medical College, Manipal. Manipal Academy of Higher Education, Manipal, 576104, India.
Sci Rep. 2024 Dec 28;14(1):31042. doi: 10.1038/s41598-024-82264-3.
Cyclophosphamide (CY) exposure is known to affect the ovary and impair fertility. Clinically, treatment is generally given over multiple doses, but research models have generally used single doses. The relative effects of administering multiple small doses of CY in the prepubertal period are not elucidated. Two-week-old early-prepubertal Swiss albino female mice were administered with either large single (200 mg/Kg x 1; CY200X1) or small multiple (75 mg/Kg x 4; CY75X4) CY doses, thus a 50% higher total dose. Surviving females were assessed for estrous cyclicity, ovarian follicle reserve, oocyte functional competence, and postnatal assessment of first-generation (F1) pups. Exposure to CY75X4 reduced the loss of ovarian follicles (p < 0.05), and body weight (p < 0.001), and resulted in a larger population of cycling females (p < 0.01) with higher oocyte yield (p < 0.05) compared to CY200X1. Although CY200X1 exposed cycling females had comparable oocyte quality, and fertility index, the postnatal mortality was higher in F1 pups (p < 0.05) in comparison to the CY75X4 group. Although both strategies affect oocyte quality and functional competence similarly, CY75X4, despite the higher overall dose, results in reduced follicle loss, produces higher oocyte/blastocyst yield, and exhibits lower postnatal mortality rates, suggesting a potential advantage over CY200X1 for later fertility and offspring health. The differences in effects of the two treatment models show the need for designing animal model studies that more closely mimic the clinical administration of gonadotoxic therapies such as cyclophosphamide.
已知环磷酰胺(CY)暴露会影响卵巢并损害生育能力。临床上,治疗通常采用多剂量给药,但研究模型一般使用单剂量。青春期前给予多小剂量CY的相对影响尚未阐明。对两周龄青春期前的瑞士白化雌性小鼠给予大剂量单剂量(200 mg/Kg×1;CY200X1)或小剂量多剂量(75 mg/Kg×4;CY75X4)CY,因此总剂量高出50%。对存活的雌性小鼠进行发情周期、卵巢卵泡储备、卵母细胞功能能力评估以及对第一代(F1)幼崽的产后评估。与CY200X1相比,CY75X4暴露减少了卵巢卵泡的损失(p<0.05)和体重(p<0.001),并导致更多的周期性发情雌性小鼠(p<0.01),卵母细胞产量更高(p<0.05)。虽然CY200X1暴露的周期性发情雌性小鼠的卵母细胞质量和生育指数相当,但与CY75X4组相比,F1幼崽的产后死亡率更高(p<0.05)。尽管两种给药策略对卵母细胞质量和功能能力的影响相似,但CY75X4尽管总剂量较高,但导致卵泡损失减少,产生更高的卵母细胞/囊胚产量,并表现出较低的产后死亡率,这表明在后期生育能力和后代健康方面比CY200X1具有潜在优势。两种治疗模型效果的差异表明,需要设计更能紧密模拟环磷酰胺等性腺毒性疗法临床给药的动物模型研究。